Home›Anthracycline

Anthracycline

11 interactions on record

Anthracycline has 11 known drug interactions based on U.S. FDA drug labeling data. 10 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Doxorubicin, Doxorubicin Hydrochloride, Epirubicin Hydrochloride. Patients taking Anthracycline should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 11
Major: 10

Major (10)

Anthracycline + Doxorubicin— Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If anthracycli…
Anthracycline + Doxorubicin Hydrochloride— Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If anthracycli…
Anthracycline + Epirubicin Hydrochloride— Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. Monitor the pa…
Anthracycline + Margetuximab-Cmkb— 7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracyclines less than 4 months after stopping MARGENZA [see C…
Anthracycline + Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf— 7 DRUG INTERACTIONS Patients who receive anthracycline after stopping PHESGO may be at increased risk of cardiac dysfunc…
Anthracycline + Trastuzumab— 7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at incr…
Anthracycline + Trastuzumab And Hyaluronidase-Oysk— 7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping HERCEPTIN HYLECTA may be at increas…
Anthracycline + Trastuzumab-Anns— 7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at incr…
Anthracycline + Trastuzumab-Dkst— 7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at incr…
Anthracycline + Trastuzumab-Qyyp— 7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at incr…

Anthracycline + Doxorubicin⚠️Major

Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If anthracyclines are used before this time, carefully monitor cardiac function.

Anthracycline + Doxorubicin Hydrochloride⚠️Major

Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If anthracyclines are used before this time, carefully monitor cardiac function.

Anthracycline + Epirubicin Hydrochloride⚠️Major

Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. Monitor the patient's cardiac function closely if anthracyclines are used before this time.

Anthracycline + Margetuximab-Cmkb⚠️Major

7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracyclines less than 4 months after stopping MARGENZA [see Clinical Pharmacology (12.3) ] may be at increased risk of cardiac dysfunction. Avoid anthracycline-based therapy for up to 4 months after stopping MARGENZA.

Anthracycline + Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf⚠️Major

7 DRUG INTERACTIONS Patients who receive anthracycline after stopping PHESGO may be at increased risk of cardiac dysfunction because of PHESGO's long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping PHESGO. If anthracyclines are used, carefully monitor the patient's cardiac function.

Anthracycline + Trastuzumab⚠️Major

7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab products' estimated long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, closely monitor the patient's cardiac function.

Anthracycline + Trastuzumab And Hyaluronidase-Oysk⚠️Major

7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping HERCEPTIN HYLECTA may be at increased risk of cardiac dysfunction because of HERCEPTIN HYLECTA's estimated long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping HERCEPTIN HYLECTA. If anthracyclines are used, closely monitor the patient's cardiac function.

Anthracycline + Trastuzumab-Anns⚠️Major

7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab products estimated long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, closely monitor the patient's cardiac function.

Anthracycline + Trastuzumab-Dkst⚠️Major

7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab products estimated long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, closely monitor the patient’s cardiac function.

Anthracycline + Trastuzumab-Qyyp⚠️Major

7 DRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab products estimated long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, closely monitor the patient's cardiac function.

Anthracycline + Cyclosporineℹ️Unknown

When coadministering ambrisentan with cyclosporine, the ambrisentan dose should not be titrated to the recommended maximum daily dose Anthracycline antibiotics High doses of cyclosporine (e.g., at starting intravenous dose of 16 mg/kg/day) may increase the exposure to anthracycline antibiotics (e.g., doxorubicin, mitoxantrone, daunorubicin) in cancer patients.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.